カテゴリ： Allied Market Research, 世界, 医療/バイオ

マイコプラズマ検査のグローバル市場（2023-2032）：機器、キット＆試薬、サービス

■ 英語タイトル：Mycoplasma Testing Market By Product (Instruments, Kits and Reagents, Services), By Technology (PCR, ELISA, Microbial Culture Techniques, Enzymatic Methods), By Application (Cell Line Testing, Virus Testing, End of Production Cells Testing, Others), By End User (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical and Biotechnology Companies, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23SEP119）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23SEP119
■ 発行日：2023年4月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：400
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[マイコプラズマ検査のグローバル市場（2023-2032）：機器、キット＆試薬、サービス]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

マイコプラズマ検査市場は、2022年には7億ドルと評価され、2023年から2032年までの年平均成長率は11.7%で、2032年には22億4,310万ドルに達すると予測されています。マイコプラズマ検査は、細胞培養サンプル中のマイコプラズマ汚染の有無を検出するために使用されます。マイコプラズマは細胞壁を持たない細菌の一種で、検出や細胞培養からの除去が困難です。マイコプラズマの混入は、細胞培養において、増殖特性の変化、遺伝子発現の変化、実験結果の悪化など、様々な問題を引き起こす可能性があります。したがって、実験結果の正確性と信頼性を保証するために、細胞培養物のマイコプラズマ汚染を定期的に検査することが不可欠です。マイコプラズマ検査は、ワクチン、ウイルス培養、その他のバイオ医薬品の検査プロセスにおいて重要です。

マイコプラズマ検査市場の成長は、生物製剤やバイオシミラーの需要の増加、細胞培養の汚染事例の急増、医薬品開発のための新技術の採用の増加によってもたらされます。生物製剤やバイオシミラーは生きた細胞を用いて製造される複雑な医薬品であり、製造過程でマイコプラズマに汚染される可能性があります。そのため、食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関は、生物製剤やバイオシミラーが承認される前にマイコプラズマに汚染されていないか検査することを義務付けています。このため、マイコプラズマ検査サービスの需要が急増しています。例えば、2021年の欧州におけるバイオシミラー競争の影響に関するIQVIAのレポートによると、2020年には約9つのバイオシミラーが承認され、2021年には7つのバイオシミラーが承認されました。このように、生物製剤とバイオシミラーの承認と需要の増加は、マイコプラズマ検査の需要の増加をもたらしました。

さらに、バイオ医薬品業界における細胞培養汚染の増加や臨床試験のグローバル化は、市場成長を後押しする主な要因です。臨床試験は複数の国や地域で実施されるため、試験参加者の安全性と試験データの正確性を確保できるマイコプラズマ検査サービスが求められています。そのため、標準化された検査要件を満たすマイコプラズマ検査サービスや製品に対する需要が高まっています。

しかし、マイコプラズマ検査製品のコストが高いため、バイオ医薬品企業での採用が制限され、それが市場の成長を抑制しています。例えば、細胞培養におけるマイコプラズマ汚染の検出に使用されるSouthernBiotech社のMycoplasma Detection Kitの価格は約200〜230ドルです。さらに、培養ベースのマイコプラズマ検査サービスの価格は、サンプルあたり約250-300ドルです。このように、マイコプラズマ検査製品やサービスのコストが高いことは、市場の成長にマイナスの影響を与えます。
一方、米国、ドイツ、中国などの先進国や発展途上国におけるマイコプラズマ検査需要の増加は、予測期間中にマイコプラズマ検査市場に大きなビジネスチャンスをもたらすと期待されています。

マイコプラズマ検査市場は、製品、技術、用途、エンドユーザー、地域によって区分されます。製品ベースでは、市場は機器、キット＆試薬、サービスに分類されます。技術ベースでは、市場はPCR法、ELISA法、微生物培養法、酵素法に分類されます。アプリケーション別では、細胞株検査、ウイルス検査、生産終了細胞検査、その他に分類されます。エンドユーザー別では、学術研究機関、セルバンク、受託研究機関、製薬・バイオテクノロジー企業、その他に分類されます。

地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（中国、日本、インド、オーストラリア、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、サウジアラビア、南アフリカ、その他のLAMEA地域）で分析します。世界のマイコプラズマ検査市場で事業を展開する主な主要企業は、ATCC、Bionique Testing Laboratories LLC、Bio-Rad Laboratories, Inc.、Charles River Laboratories、Eurofins Scientific、F. Hoffmann-La Roche Ltd.、InvivoGen、Lonza、Norgen Biotek Corp.、Thermo Fisher Scientific Inc.です。同市場で事業を展開する主要企業は、製品ポートフォリオを拡大するための主要戦略として、製品承認、買収、製品上市を採用しています。

ステークホルダーにとっての主な利点
当レポートは、2022年から2032年までのマイコプラズマ検査市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、優勢なマイコプラズマ検査市場機会を特定します。
市場調査は、主要な促進要因、阻害要因、機会に関する情報とともに提供されます。
ポーターのファイブフォース（5つの力）分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの潜在力を明らかにします。
マイコプラズマ検査市場のセグメンテーションの詳細な分析により、市場機会を決定します。
各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
本レポートには、地域別および世界別のマイコプラズマ検査市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

主な市場セグメント
製品別
機器
キットと試薬
サービス

技術別
PCR法
ELISA
微生物培養技術
酵素法

アプリケーション別
細胞株検査
ウイルス検査
生産終了細胞検査
その他

エンドユーザー別
学術研究機関
細胞バンク
受託研究機関
製薬・バイオテクノロジー企業
その他

地域別
北米
米国
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主な市場プレイヤー
○ ATCC
○ Bionique Testing Laboratories LLC
○ Bio-Rad Laboratories, Inc. 
○ Charles River Laboratories
○ Eurofins Scientific
○ F. Hoffmann-La Roche Ltd.
○ InvivoGen
○ Lonza
○ Norgen Biotek Corp.
○ Thermo Fisher Scientific Inc. 

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：マイコプラズマ検査市場、製品別
第5章：マイコプラズマ検査市場、技術別
第6章：マイコプラズマ検査市場、用途別
第7章：マイコプラズマ検査市場、エンドユーザー別
第8章：マイコプラズマ検査市場、地域別
第9章：競争状況
第10章：企業情報

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in demand for mycoplasma testing
3.4.1.2. Increase in incidences of cell culture contamination

3.4.2. Restraints
3.4.2.1. High cost of mycoplasma testing kits and instruments

3.4.3. Opportunities
3.4.3.1. Developing economies offer lucrative opportunities
3.4.3.2. Rise in technological advancements

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: MYCOPLASMA TESTING MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Instruments
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Kits and Reagents
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Services
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: MYCOPLASMA TESTING MARKET, BY TECHNOLOGY
5.1. Overview
5.1.1. Market size and forecast
5.2. PCR
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. ELISA
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Microbial Culture Techniques
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Enzymatic Methods
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: MYCOPLASMA TESTING MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Cell Line Testing
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Virus Testing
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. End of Production Cells Testing
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: MYCOPLASMA TESTING MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Academic Research Institutes
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Cell Banks
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Contract Research Organizations
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
7.5. Pharmaceutical and Biotechnology Companies
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by region
7.5.3. Market share analysis by country
7.6. Others
7.6.1. Key market trends, growth factors and opportunities
7.6.2. Market size and forecast, by region
7.6.3. Market share analysis by country
CHAPTER 8: MYCOPLASMA TESTING MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Product
8.2.3. Market size and forecast, by Technology
8.2.4. Market size and forecast, by Application
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Product
8.2.6.1.3. Market size and forecast, by Technology
8.2.6.1.4. Market size and forecast, by Application
8.2.6.1.5. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Product
8.2.6.2.3. Market size and forecast, by Technology
8.2.6.2.4. Market size and forecast, by Application
8.2.6.2.5. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Product
8.2.6.3.3. Market size and forecast, by Technology
8.2.6.3.4. Market size and forecast, by Application
8.2.6.3.5. Market size and forecast, by End User
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Product
8.3.3. Market size and forecast, by Technology
8.3.4. Market size and forecast, by Application
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Product
8.3.6.1.3. Market size and forecast, by Technology
8.3.6.1.4. Market size and forecast, by Application
8.3.6.1.5. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Product
8.3.6.2.3. Market size and forecast, by Technology
8.3.6.2.4. Market size and forecast, by Application
8.3.6.2.5. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Product
8.3.6.3.3. Market size and forecast, by Technology
8.3.6.3.4. Market size and forecast, by Application
8.3.6.3.5. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Product
8.3.6.4.3. Market size and forecast, by Technology
8.3.6.4.4. Market size and forecast, by Application
8.3.6.4.5. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Product
8.3.6.5.3. Market size and forecast, by Technology
8.3.6.5.4. Market size and forecast, by Application
8.3.6.5.5. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Product
8.3.6.6.3. Market size and forecast, by Technology
8.3.6.6.4. Market size and forecast, by Application
8.3.6.6.5. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Product
8.4.3. Market size and forecast, by Technology
8.4.4. Market size and forecast, by Application
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Product
8.4.6.1.3. Market size and forecast, by Technology
8.4.6.1.4. Market size and forecast, by Application
8.4.6.1.5. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Product
8.4.6.2.3. Market size and forecast, by Technology
8.4.6.2.4. Market size and forecast, by Application
8.4.6.2.5. Market size and forecast, by End User
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Product
8.4.6.3.3. Market size and forecast, by Technology
8.4.6.3.4. Market size and forecast, by Application
8.4.6.3.5. Market size and forecast, by End User
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Product
8.4.6.4.3. Market size and forecast, by Technology
8.4.6.4.4. Market size and forecast, by Application
8.4.6.4.5. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Product
8.4.6.5.3. Market size and forecast, by Technology
8.4.6.5.4. Market size and forecast, by Application
8.4.6.5.5. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Product
8.4.6.6.3. Market size and forecast, by Technology
8.4.6.6.4. Market size and forecast, by Application
8.4.6.6.5. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Product
8.5.3. Market size and forecast, by Technology
8.5.4. Market size and forecast, by Application
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Product
8.5.6.1.3. Market size and forecast, by Technology
8.5.6.1.4. Market size and forecast, by Application
8.5.6.1.5. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Product
8.5.6.2.3. Market size and forecast, by Technology
8.5.6.2.4. Market size and forecast, by Application
8.5.6.2.5. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Product
8.5.6.3.3. Market size and forecast, by Technology
8.5.6.3.4. Market size and forecast, by Application
8.5.6.3.5. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Product
8.5.6.4.3. Market size and forecast, by Technology
8.5.6.4.4. Market size and forecast, by Application
8.5.6.4.5. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Thermo Fisher Scientific Inc. 
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Charles River Laboratories
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.3. Lonza
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. F. Hoffmann-La Roche Ltd.
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Bio-Rad Laboratories, Inc. 
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.6. Eurofins Scientific
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. ATCC
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.8. Bionique Testing Laboratories LLC
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.9. InvivoGen
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.10. Norgen Biotek Corp.
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio

LIST OF TABLES
TABLE 01. GLOBAL MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 02. MYCOPLASMA TESTING MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. MYCOPLASMA TESTING MARKET FOR KITS AND REAGENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. MYCOPLASMA TESTING MARKET FOR SERVICES, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 06. MYCOPLASMA TESTING MARKET FOR PCR, BY REGION, 2022-2032 ($MILLION)
TABLE 07. MYCOPLASMA TESTING MARKET FOR ELISA, BY REGION, 2022-2032 ($MILLION)
TABLE 08. MYCOPLASMA TESTING MARKET FOR MICROBIAL CULTURE TECHNIQUES, BY REGION, 2022-2032 ($MILLION)
TABLE 09. MYCOPLASMA TESTING MARKET FOR ENZYMATIC METHODS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 11. MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY REGION, 2022-2032 ($MILLION)
TABLE 12. MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY REGION, 2022-2032 ($MILLION)
TABLE 13. MYCOPLASMA TESTING MARKET FOR END OF PRODUCTION CELLS TESTING, BY REGION, 2022-2032 ($MILLION)
TABLE 14. MYCOPLASMA TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 16. MYCOPLASMA TESTING MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
TABLE 17. MYCOPLASMA TESTING MARKET FOR CELL BANKS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. MYCOPLASMA TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 19. MYCOPLASMA TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
TABLE 20. MYCOPLASMA TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 21. MYCOPLASMA TESTING MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 25. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 27. U.S. MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 28. U.S. MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 29. U.S. MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 30. U.S. MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 31. CANADA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 32. CANADA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 33. CANADA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 34. CANADA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 35. MEXICO MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 36. MEXICO MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 37. MEXICO MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. MEXICO MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. EUROPE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 40. EUROPE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 41. EUROPE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. EUROPE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 43. EUROPE MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 44. GERMANY MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 45. GERMANY MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 46. GERMANY MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. GERMANY MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 48. FRANCE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 49. FRANCE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 50. FRANCE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. FRANCE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 52. UK MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 53. UK MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 54. UK MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. UK MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 56. ITALY MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 57. ITALY MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 58. ITALY MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. ITALY MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 60. SPAIN MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 61. SPAIN MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 62. SPAIN MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. SPAIN MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 65. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 66. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 70. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 71. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 72. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 73. JAPAN MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 74. JAPAN MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 75. JAPAN MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. JAPAN MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 77. CHINA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 78. CHINA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 79. CHINA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 80. CHINA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 81. AUSTRALIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 82. AUSTRALIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 83. AUSTRALIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 84. AUSTRALIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 85. INDIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 86. INDIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 87. INDIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. INDIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 90. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 91. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 92. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 95. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 96. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 97. LAMEA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 98. LAMEA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 99. LAMEA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 100. LAMEA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 101. LAMEA MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 102. BRAZIL MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 103. BRAZIL MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 104. BRAZIL MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 105. BRAZIL MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 106. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 107. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 108. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 109. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 110. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 111. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 112. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 113. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 114. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 115. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 116. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 117. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 118. THERMO FISHER SCIENTIFIC INC. : KEY EXECUTIVES
TABLE 119. THERMO FISHER SCIENTIFIC INC. : COMPANY SNAPSHOT
TABLE 120. THERMO FISHER SCIENTIFIC INC. : PRODUCT SEGMENTS
TABLE 121. THERMO FISHER SCIENTIFIC INC. : SERVICE SEGMENTS
TABLE 122. THERMO FISHER SCIENTIFIC INC. : PRODUCT PORTFOLIO
TABLE 123. CHARLES RIVER LABORATORIES: KEY EXECUTIVES
TABLE 124. CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
TABLE 125. CHARLES RIVER LABORATORIES: SERVICE SEGMENTS
TABLE 126. CHARLES RIVER LABORATORIES: PRODUCT PORTFOLIO
TABLE 127. LONZA: KEY EXECUTIVES
TABLE 128. LONZA: COMPANY SNAPSHOT
TABLE 129. LONZA: PRODUCT SEGMENTS
TABLE 130. LONZA: SERVICE SEGMENTS
TABLE 131. LONZA: PRODUCT PORTFOLIO
TABLE 132. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 133. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 134. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 135. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 136. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
TABLE 137. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
TABLE 138. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
TABLE 139. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
TABLE 140. EUROFINS SCIENTIFIC: KEY EXECUTIVES
TABLE 141. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
TABLE 142. EUROFINS SCIENTIFIC: SERVICE SEGMENTS
TABLE 143. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 144. ATCC: KEY EXECUTIVES
TABLE 145. ATCC: COMPANY SNAPSHOT
TABLE 146. ATCC: PRODUCT SEGMENTS
TABLE 147. ATCC: SERVICE SEGMENTS
TABLE 148. ATCC: PRODUCT PORTFOLIO
TABLE 149. BIONIQUE TESTING LABORATORIES LLC: KEY EXECUTIVES
TABLE 150. BIONIQUE TESTING LABORATORIES LLC: COMPANY SNAPSHOT
TABLE 151. BIONIQUE TESTING LABORATORIES LLC: PRODUCT SEGMENTS
TABLE 152. BIONIQUE TESTING LABORATORIES LLC: SERVICE SEGMENTS
TABLE 153. BIONIQUE TESTING LABORATORIES LLC: PRODUCT PORTFOLIO
TABLE 154. INVIVOGEN: KEY EXECUTIVES
TABLE 155. INVIVOGEN: COMPANY SNAPSHOT
TABLE 156. INVIVOGEN: PRODUCT SEGMENTS
TABLE 157. INVIVOGEN: SERVICE SEGMENTS
TABLE 158. INVIVOGEN: PRODUCT PORTFOLIO
TABLE 159. NORGEN BIOTEK CORP.: KEY EXECUTIVES
TABLE 160. NORGEN BIOTEK CORP.: COMPANY SNAPSHOT
TABLE 161. NORGEN BIOTEK CORP.: PRODUCT SEGMENTS
TABLE 162. NORGEN BIOTEK CORP.: SERVICE SEGMENTS
TABLE 163. NORGEN BIOTEK CORP.: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • パイロジェン検査のグローバル市場（2023-2032）：試薬・キット、機器、サービス
  • 遠隔皮膚科のグローバル市場（2023-2032）：製品、サービス
  • 通信ネットワークインフラのグローバル市場（2023-2032）：製品、サービス
  • 細胞解析のグローバル市場（2023-2032）：消耗品、サービス、機器、ソフトウェア
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23SEP119 )"マイコプラズマ検査のグローバル市場（2023-2032）：機器、キット＆試薬、サービス" (英文：Mycoplasma Testing Market By Product (Instruments, Kits and Reagents, Services), By Technology (PCR, ELISA, Microbial Culture Techniques, Enzymatic Methods), By Application (Cell Line Testing, Virus Testing, End of Production Cells Testing, Others), By End User (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical and Biotechnology Companies, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。